Tellusgruppen AB vs Fredun Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Tellusgruppen AB (TELLUS) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Tellusgruppen AB trades at SEK 6.20 versus a fair value of SEK 3.73 (-40%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).
Tellusgruppen AB
TELLUS.ST · SEK · Consumer Discretionary
-40%
upside to fair value
overvalued
PriceSEK 6.20
Fair ValueSEK 3.73
Quality52/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
+77%
upside to fair value
undervalued
Price₹1,218
Fair Value₹2,155
Quality33/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Tellusgruppen ABFredun Pharmaceuticals
Valuation
22.2×P/E (TTM)42.2×
0.22×P/S (TTM)2.23×
—P/B5.03×
2.9×EV/EBITDA15.5×
2.2%Dividend yield0.0%
SEK 0.13Dividend per share₹0.70
Profitability
1%Net margin5%
2%Operating margin12%
21%Return on equity16%
3%Return on assets9%
Growth
6%Revenue growth (YoY)27%
14.8%Avg. growth/yr (3Y)32.2%
21.2%Avg. growth/yr (5Y)36.9%
Balance & size
6.34×Debt / equity0.20×
$11MMarket cap$149M
healthyGrowth qualityexpensive
Fredun Pharmaceuticals leads: 5 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Tellusgruppen ABof which business quality 51 · market factors 61Fredun Pharmaceuticalsof which business quality 35 · market factors 44
ProfitabilityMargins and returns on capital today
52
48
Quality GrowthAre margins and returns improving?
68
73
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
100
16
Low VolatilityCalm price path (market factor)
51
43
MomentumPrice trend over the last 3–12 months (market factor)
58
39
52W MomentumDistance to the 52-week high (market factor)
78
54
Net IssuanceBuybacks instead of dilution
0
7
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Tellusgruppen AB
DCF ModelsSEK 24.69
Earnings-BasedSEK 5.53
Dividend DiscountSEK 1.14
MultiplesSEK 4.39
Asset-BasedSEK 0.03
Growth DCFSEK 31.78
Economic ProfitSEK 0.32
Growth EarningsSEK 7.56
10 of 23 models see the stock below the current price.
Fredun Pharmaceuticals
Earnings-Based₹1,942
Multiples₹1,723
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,535
5 of 14 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Tellusgruppen AB
Bear SEK 2.80Fair Value SEK 3.73Bull SEK 4.67
SEK 6.20 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,509Fair Value ₹2,155Bull ₹2,802
₹1,218 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Tellusgruppen AB · Consumer Discretionary
Quality score52 · below median
Fair value upside-40% · below median
Fredun Pharmaceuticals · Healthcare
Quality score33 · bottom 25%
Fair value upside+77% · Top 25%
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Tellusgruppen AB trades at SEK 6.20 versus a fair value of SEK 3.73 (-40%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).
Tellusgruppen AB has the higher quality score (52/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
